
MediciNova MNOV
$ 1.44
-1.37%
MediciNova EBITDA per Share | MNOV
Annual EBITDA per Share MediciNova
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.27 | -0.26 | -0.2 | -0.3 | -0.21 | -0.317 | -0.325 | -0.378 | -0.37 | -0.329 | -0.331 | -0.382 | -0.189 | -0.63 | -1.08 | -1.43 | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.189 | -1.43 | -0.438 |
Quarterly EBITDA per Share MediciNova
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.06 | - | - | - | -0.07 | - | - | - | -0.06 | - | - | - | -0.06 | - | -0.08 | -0.08 | -0.07 | - | -0.07 | -0.09 | - | - | -0.08 | -0.1 | -0.07 | - | -0.06 | -0.1 | -0.12 | - | -0.17 | -0.08 | -0.12 | - | -0.11 | -0.08 | -0.09 | - | -0.08 | -0.1 | -0.11 | - | -0.06 | -0.09 | -0.09 | - | -0.1 | -0.09 | -0.1 | - | -0.1 | -0.13 | -0.13 | - | -0.14 | -0.14 | -0.24 | - | -0.25 | -0.24 | -0.31 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.06 | -0.31 | -0.11 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
SIGA Technologies
SIGA
|
0.34 | $ 3.12 | 4.55 % | $ 223 M | ||
|
Sage Therapeutics
SAGE
|
-7.1 | - | - | $ 527 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
1.33 | - | - | $ 1.62 B | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
-2.67 | $ 61.62 | -2.21 % | $ 172 M | ||
|
SELLAS Life Sciences Group
SLS
|
-0.26 | $ 8.41 | 6.73 % | $ 917 M | ||
|
Summit Therapeutics
SMMT
|
-0.31 | $ 16.34 | 15.15 % | $ 12.2 B | ||
|
Cabaletta Bio
CABA
|
-1.7 | $ 1.3 | 1.17 % | $ 131 M | ||
|
Syndax Pharmaceuticals
SNDX
|
-3.08 | $ 9.53 | 1.39 % | $ 826 M | ||
|
Sanofi
SNY
|
5.2 | $ 47.06 | 0.32 % | $ 57.4 B | ||
|
Forma Therapeutics Holdings
FMTX
|
-3.64 | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
0.26 | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
4.4 | - | - | $ 26.6 B | ||
|
Sarepta Therapeutics
SRPT
|
-6.54 | $ 17.8 | 0.68 % | $ 1.78 B | ||
|
Paratek Pharmaceuticals
PRTK
|
-0.84 | - | - | $ 121 M | ||
|
China SXT Pharmaceuticals
SXTC
|
-10.4 | $ 2.84 | -3.07 % | $ 1.93 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
217 | $ 21.02 | -0.92 % | $ 33.2 B | ||
|
Tarsus Pharmaceuticals
TARS
|
-1.68 | $ 68.11 | 0.87 % | $ 2.85 B | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
-0.09 | - | -14.27 % | $ 1.7 M | ||
|
Bio-Techne Corporation
TECH
|
2.24 | $ 72.78 | 0.17 % | $ 11.4 B | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
2.76 | $ 42.32 | 1.33 % | $ 48.5 B | ||
|
RedHill Biopharma Ltd.
RDHL
|
-0.07 | $ 0.43 | 0.45 % | $ 5.3 B | ||
|
Adverum Biotechnologies
ADVM
|
-6.85 | - | - | $ 86.2 M | ||
|
Unity Biotechnology
UBX
|
-1.8 | - | -33.41 % | $ 3.37 M | ||
|
iTeos Therapeutics
ITOS
|
-3.91 | - | - | $ 411 M | ||
|
Shattuck Labs
STTK
|
-0.69 | $ 4.59 | 2.78 % | $ 319 M | ||
|
Seelos Therapeutics
SEEL
|
-8.26 | - | -47.76 % | $ 6.27 M | ||
|
Evogene Ltd.
EVGN
|
-1.78 | $ 0.28 | -16.14 % | $ 2.2 M | ||
|
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | ||
|
Protara Therapeutics
TARA
|
-1.5 | $ 2.33 | 9.15 % | $ 99.8 M | ||
|
Trevi Therapeutics
TRVI
|
-0.37 | $ 14.33 | 11.87 % | $ 1.93 B | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
0.09 | $ 4.63 | 21.05 % | $ 20 M | ||
|
Fennec Pharmaceuticals
FENC
|
-0.22 | $ 9.79 | 4.26 % | $ 280 M | ||
|
Kiromic BioPharma
KRBP
|
-14.1 | - | 6.61 % | $ 3.08 M | ||
|
CNS Pharmaceuticals
CNSP
|
-36 | $ 3.92 | -2.24 % | $ 1.74 M | ||
|
Calithera Biosciences
CALA
|
-9.02 | - | -10.95 % | $ 876 K | ||
|
United Therapeutics Corporation
UTHR
|
35.6 | $ 562.14 | -0.63 % | $ 24.9 B | ||
|
Vericel Corporation
VCEL
|
0.45 | $ 54.56 | 5.36 % | $ 2.75 B | ||
|
Veracyte
VCYT
|
1.01 | $ 24.1 | 0.42 % | $ 1.89 B | ||
|
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | ||
|
Fulcrum Therapeutics
FULC
|
-1.32 | $ 3.72 | 0.95 % | $ 236 M | ||
|
Molecular Templates
MTEM
|
-0.85 | - | -23.43 % | $ 495 K | ||
|
Vanda Pharmaceuticals
VNDA
|
-2.55 | $ 3.82 | 6.27 % | $ 225 M | ||
|
Verrica Pharmaceuticals
VRCA
|
-1.13 | $ 3.22 | 4.21 % | $ 34.3 M | ||
|
Viridian Therapeutics
VRDN
|
-3.56 | $ 28.47 | -0.28 % | $ 2.9 B | ||
|
BioXcel Therapeutics
BTAI
|
-4.11 | $ 0.07 | 9.81 % | $ 855 K | ||
|
VistaGen Therapeutics
VTGN
|
-1.89 | $ 0.17 | 3.45 % | $ 6.47 M | ||
|
Voyager Therapeutics
VYGR
|
-2.18 | $ 1.86 | 8.14 % | $ 109 M | ||
|
CohBar
CWBR
|
-4.24 | - | -15.44 % | $ 2.2 M | ||
|
NeuBase Therapeutics
NBSE
|
-0.12 | - | -1.56 % | $ 12.3 M | ||
|
Gossamer Bio
GOSS
|
-0.75 | $ 9.77 | 3.72 % | $ 2.23 B |